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T3P-DMSO mediated synthesisA new, simple, and microwave-assisted, solution-phase T3P-DMSO mediated method for the prepara-
tion of a novel class of estrogen receptor alpha (ERa) ligands based on the 2-phenylquinoline scaffold
was developed. Furthermore, the novel ERa ligands were tested for their bioactivity against ERa-positive
and ERa-negative cell lines. The ligand (entry 4), with amine and nitro group substitution at C4 position,
displayed signiﬁcant cytotoxicity against MCF-7 and HepG2 cells with an IC50 value of 6 and 11 lM,
respectively. On the other hand, ERa-negative cells displayed resistance to quinolines induced cytotoxi-
city with an IC50 value >100 Mm and they does not induce cytotoxicity in normal breast epithelial cells.
Molecular docking analyses suggest a consistent binding mode for these ERa ligands in the ligand binding
domain of the human ERa and predict the ligands to occupy the hydrophobic cavity in a similar fashion as
estradiol or GW2368.
 2015 Elsevier Ltd. All rights reserved.Breast cancer is a leading cancer in women worldwide and con-
tributing to second cause of lethality after lung cancer.1,2 Most
breast cancers are associated with interaction of estrogen receptors
(ER) in the breast epithelial cells to estrogen. The physiological
action of estrogen is induced via two types of estrogen receptors
namely ERa and ERb.3 Research in the previous decade revealed
that more than 70% of breast cancers are due to ERa dependent
epithelial cell proliferation. The role of ERb is not clear in initiation
and progression of breast cancer.4 ERa belongs to nuclear receptor
superfamily which regulates the transcription of genes involved in
proliferation, anti-apoptosis, metastasis and immunosurveil-
lance.5–7 The binding of 17b-estradiol to ERa induces the receptor
dimerization and facilitates binding of the ligand-receptor complex
to the promoter of target genes.8 Also, ER-dependent pathways
regulate the synthesis and distribution of glycosaminoglycans in
cancer cells.9 Several small molecule ERa antagonists includingTamoxifen, Raloxifene and Fulvestrant have been implemented in
the treatment of breast cancer.10,11 Benzisoxazole tethered azoles
have known to be the better ER ligands.12–14 Therefore, probing
small molecules against ERa is considered to be the most attractive
therapeutic target to treat breast cancer (Fig. 1).15
Quinoline derivatives are the pharmacologically important
heterocycles which have been studied extensively for their
anticancer properties. Multiple reports have demonstrated the
preparation of quinolines using strong base like tertiary
butoxide.16,17 We previous reported the anti-cancer effect of vari-
ous heterocyclic compounds18–20 and recently reported the solu-
tion phase synthesis of 2-amino-chromene-3-carbonitriles from
alcohols, malanonitrile and phenols.21 Using a similar strategy,
herein, we report a simple and efﬁcient method for the preparation
of T3P-DMSO mediated 2-phenylquinoline derivatives using
amino alcohols and acetophenones under microwave irradiation
and evaluated for their cytotoxicity. The newly developed method
was generalized using variety of aromatic 2-amino alcohols and
Scheme 1. Schematic representation of the synthesis of quinoline-based ERa ligands.
Figure 1. ERa scaffold evolution.
Table 1
The physical characterization of new quinoline-based ERa ligands, whose core
scaffold has different substitutions at R1–R6 positions
Entry R1 R2 R3 R4 R5 R6 Y Mp (C)
1 H H OH H H H 85 52
2 CH3 H Br H H H 89 50
3 H H Cl H Cl H 92 70
4 H Cl H H NH2 H 95 60
5 CH3 H Cl H Cl H 90 59
6 H H H H Br H 88 63
7 CH3 H H H H H 87 54
8 CH3 H H H NH2 H 91 67
9 CH3 H OH H H OH 89 54
10 CH3 H H NO2 H H 93 64
Table 2
Cytotoxicity data for the new ERa ligands IC50 against human cancer cells
Entry ERa-positive cells ERa-negative cells Breast
epithelial cells
MCF-7
(lM)
HepG2
(lM)
MDA-MB-231
(lM)
BT549
(lM)
MCF-10A (lM)
1 >50 >50 NT NT NT
2 >50 >50 NT NT NT
3 25 31.6 >100 >100 >100
4 6 11 >100 >100 >100
5 >50 >50 NT NT NT
6 12 9 >100 >100 60.3
7 >50 >50 NT NT NT
8 34 41 NT NT NT
9 28 19 NT NT NT
10 23 37 >100 >100 >100
⁄NT—not tested.
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(Scheme 1; Table 1). Our docking analysis validated the interaction
of quinoline derivatives with the estrogen receptor in the similar
fashion as estradiol to induce its anticancer effect.
Additionally, all the new molecules were characterized com-
pletely using IR, 1H NMR, 13C NMR, and LC–MS spectral analysis
(please refer Supplementary data).
Further, the library of ERa ligands was tested for its cytotoxicity
against ERa-positive, ERa-negative cancer cells and their
counterpart non-diseased breast epithelial cells as described pre-
viously and detailed methodology is provided in Supplementary
information.22,23 The results are summarized in Table 2.
Among the tested compounds 4, 6, and 10 signiﬁcantly inhibited
the proliferation of ERa-positive cells. Further, compounds (4, 6, and
10) with high cytotoxicity were tested against ERa-negative cells.
All the ERa-negative cells were resistance to the lead compounds
with IC50 values more than 100 lM. However, the shortlisted three
molecules did not induce cytotoxicity onMCF-10A cells up to 72 h at
100 lM. These results indicate that the newly synthesized ERa
ligands are selectively cytotoxic against ERa expressing cancer cells
and does not interfere with viability of their counterpart.
Additionally, the structural models for molecular interactions
between the newer ERa ligands and the human estrogen receptor
were generated using in silico docking analysis as described pre-
viously and detailed methodology is provided in Supplementary
information.24–26 Docking was based on the co-crystal structure
of the naphthalene derivative GW2368 with the estrogen receptor
(PDB: 3DT3).27 Molecular docking suggests a consistent binding
mode for the series of quinoline-based ERa ligands in the ligand
binding domain of the human estrogen receptor. Thereby, the
compounds occupy the hydrophobic cavity in a similar fashion as
estradiol or GW2368 (Fig. 2). The docking scores of the ERa ligands
Figure 2. Predicted interactions of quinoline-based ERa molecules towards the
ligand binding domain of the human estrogen receptor. The protein is shown as
green cartoon with main polar interaction centers Arg-394, Glu-353, and His-524
highlighted as sticks in atomic coloring. Interactions of estradiol with estrogen
receptor (A) are resembled by the naphthalene-derived compound GW2368 (B) and
predicted to be similar for the quinoline series (C).
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Table 1). The quinoline scaffold of the ERa ligands occupies the
position of rings A and B in the steroid and show major overlap
with the naphthalene ring system of GW2368. Furthermore, pres-
ence of benzene substituents allows for interactions with His-524
in agreement with other estrogen receptor ligands. Presence of a
hydrogen bond donor function is predicted to facilitate a second
binding mode, where hydrogen bonds to Arg-394 and Glu-353
are formed. The structure-activity-relationship studies for the
compound 4, which bearing chlorine atom at R2 renders signiﬁcant
anti-proliferative activity towards ER positive cancer cells, whereas
the presence of methyl group at R1 decreases the activity. This
observation was evidenced with strong binding of compound 4
to ER alpha LBD, when compared to compound 8.
In conclusion, we have identiﬁed a novel quinoline-based ERa
ligands as biologically active compounds against ERa expressing
human cancer cells. This study also introduces a novel
microwave-assisted synthesis pathway to the compound series.
Therefore, method will be useful to develop libraries of quino-
line-based ERa ligands to treat breast cancer.
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